Association between SNPs in Serpin gene family and risk of esophageal squamous cell carcinoma

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 6231-6238

  Meng, Hui ^a   Guan, Xingying ^a   Guo, Hong ^a   Xiong, Gang ^a   Yang, Kang ^a   Wang, Kai ^a   Bai, Yun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Association study; Esophageal squamous cell carcinoma; Serpin; Single nucleotide polymorphism (SNP)

Indexed keywords

MESSENGER RNA; SERINE PROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERPIN-B5; SERPINE1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RISK; CANCER TISSUE; CHINA; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SERPINB2 GENE; SERPINB5 GENE; SERPINE1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; AGED; ALLELE; BIOSYNTHESIS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; MIDDLE AGED; SQUAMOUS CELL CARCINOMA;

AGED; ALLELES; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; POLYMORPHISM, SINGLE NUCLEOTIDE; SERPINS;

EID: 84940439609     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3308-3     Document Type: Article

References (35)

1. Stahl M, Budach W, Meyer HJ, Cervantes A. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v46–9.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
3. Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013;23:233–42.
4. Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X, et al. Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 2013;5:19–26.
5. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 2001;276:33293–6.
6. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994;269:15957–60.
7. Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol. 2007;20:570–8.
8. Vecchi M, Confalonieri S, Nuciforo P, Vigano MA, Capra M, Bianchi M, et al. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene. 2008;27:2148–58.
9. Jing Y, Kovacs K, Kurisetty V, Jiang Z, Tsinoremas N, Merchan JR. Role of plasminogen activator inhibitor-1 in urokinase’s paradoxical in vivo tumor suppressing or promoting effects. Mol Cancer Res. 2012;10:1271–81.
10. Klein RM, Bernstein D, Higgins SP, Higgins CE, Higgins PJ. Serpine1 expression discriminates site-specific metastasis in human melanoma. Exp Dermatol. 2012;21:551–4.
11. Ozaki K, Nagata M, Suzuki M, Fujiwara T, Miyoshi Y, Ishikawa O, et al. Isolation and characterization of a novel human pancreas-specific gene, pancpin, that is down-regulated in pancreatic cancer cells. Genes Chromosomes Cancer. 1998;22:179–85.
12. Takahashi Y, Mimori K, Mori M. Significance of genome-wide association study in cancer. Nihon Geka Gakkai Zasshi. 2012;113:210–4.
13. Wang K, Guo H, Hu H, Xiong G, Guan X, Li J, et al. A functional variation in pre-microrna-196a is associated with susceptibility of esophageal squamous cell carcinoma risk in Chinese Han. Biomarkers. 2010;15:614–8.
14. Southam L, Rodriguez-Lopez J, Wilkins JM, Pombo-Suarez M, Snelling S, Gomez-Reino JJ, et al. An snp in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet. 2007;16:2226–32.
15. Chapman K, Takahashi A, Meulenbelt I, Watson C, Rodriguez-Lopez J, Egli R, et al. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet. 2008;17:1497–504.
16. Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, et al. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res. 2011;17:7723–31.
17. Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, et al. Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A. 2011;108:13653–8.
18. Wang K, Li J, Guo H, Xu X, Xiong G, Guan X, et al. Mir-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis. 2012;33:2147–54.
19. Wang K, Liu B, Li J, Xiong G, Guan X, Yang K, et al. Association between SNPs in P53 binding regions and risk of esophageal squamous cell carcinoma. Int J Biol Markers. 2014;29:e160–8.
20. Wang JM, Xu B, Rao JY, Shen HB, Xue HC, Jiang QW. Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of esophageal squamous cell carcinoma in the Chinese population. Eur J Gastroenterol Hepatol. 2007;19:171–6.
21. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.
22. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 2005;65:9582–7.
23. Shao LJ, Shi HY, Ayala G, Rowley D, Zhang M. Haploinsufficiency of the maspin tumor suppressor gene leads to hyperplastic lesions in prostate. Cancer Res. 2008;68:5143–51.
24. Bass R, Fernandez AM, Ellis V. Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem. 2002;277:46845–8.
25. Abraham S, Zhang W, Greenberg N, Zhang M. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol. 2003;169:1157–61.
26. Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene. 2002;21:4089–98.
27. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med. 2000;6:196–9.
28. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, et al. Expression of the p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer. 2001;95:337–42.
29. Shams TM, Samaka RM, Shams ME. Maspin protein expression: a special feature of papillary thyroid carcinoma. J Egypt Natl Canc Inst. 2006;18:274–80.
30. Kim S, Han J, Kim J, Park C. Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res. 2004;64:6900–5.
31. Wang Y, Sheng S, Zhang J, Dzinic S, Li S, Fang F, et al. Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC). PLoS One. 2013;8:e63581.
32. Bieche I, Girault I, Sabourin JC, Tozlu S, Driouch K, Vidaud M, et al. Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. Br J Cancer. 2003;88:863–70.
33. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer. 2002;100:452–5.
34. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002;8:2924–32.
35. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21:7435–51.